Tom Stankovich
Chief Financial Officer, Interim President and Chief Executive Officer

Mr. Stankovich has over 25 years of executive leadership experience as the CFO for multiple public and private healthcare companies. Tom has spent the past nine years as the Global Senior Vice President and CFO of MP Biomedicals, a life sciences and molecular biology-diagnostics company. At MP Biomedicals he was responsible for financial planning and reporting, financial operations and strategy development along with the acquisition and integration of two international companies. Prior to MP Biomedicals, Tom served as CFO at Response Genetics where he successfully led the company through their initial public offering. Additionally, he served as CFO for Cobalis Corporation and for Ribapharm, where he also led the company through their initial public offering, which at the time became the second largest ever IPO in the biotechnology sector. Tom also held CFO positions at ICN International, which later changed names to Valeant Pharmaceuticals.

    Raj Nihalani, MD
    Chief Technology Officer & Business Development

    Dr. Nihalani has served as Chief Technology Officer & Business Development since May 2017, immediately following the Company’s acquisition of BarioSurg, Inc. From August 2008 to May 2017, Dr. Nihalani served as the Chief Executive Officer of BarioSurg, Inc., a privately held medical device company that developed a minimally invasive and reversible device to treat obesity and glycemic control. Dr. Nihalani has several US and international patents and has won awards for his inventions. He holds a medical degree from the University of Nagpur, India. Also, he held positions of increased responsibility at Endologix (ELGX), Medtronic (MDT), Acufocus, Inc, Rox Medical, & TrialMed Life Sciences.

      Michael Bordainick
      Senior Vice President, Commercial Operations

      Mr. Bordainick has two decades of marketing and sales management experience in leading healthcare and consumer product industries. He joins Reshape from Alcon, where he served as Global Vice President of Marketing, responsible for marketing and sales activities of the company’s $1.8 billion contact lens portfolio. Prior to that, Mr. Bordainick was the Global Marketing Director at Kimberly Clark, where he led the Kleenex, Viva and Scott brands. Earlier in his career, he spent 10 years at Unilever, where he held positions of increasing responsibility within consumer brand management.

      Mr. Bordainick holds a Bachelor of Business Administration in International Marketing and Finance from the University of Miami and an MBA from Indiana University’s Kelley School of Business.

        Al Diaz
        Vice President, Operations and R&D

        Mr. Diaz joined the company as Vice President of Operations in August of 2021. Mr. Diaz possesses over thirty years of executive leadership experience in operations and engineering in implantable and non-implantable devices. Most recently, he served as Executive Vice President of Operations at ClearFlow, Inc. Mr. Diaz also held executive operational positions at the following companies: VasoNova, Inc. (Teleflex), Cardio Output Technologies, Inc., United States Manufacturing Company, Biolase Technology, Inc., Sorin Biomedica, Italy, Laerdal Medical, and Advanced Interventional Systems. Additionally, from 2003 until 2016, he was the Owner and President of Azmec, Inc., a manufacturer, and distributor of orthopedic soft goods.

          Dov Gal, DVM, MBA
          Vice President, Regulatory Clinical Quality & Compliance Officer

          Dr. Gal joined the Company as Vice President, Regulatory Clinical Quality & Compliance Officer in September 2019. With more than 30-year experience as a practicing veterinarian, academician at Tufts University School of Medicine and subsequently in the medtech industry. Prior to joining ReShape Lifesciences, Dr. Gal held R&D, clinical marketing and clinical affairs positions in private start-up, and medium to large public medical device companies. Specifically, Dr. Gal led the regulatory, clinical and quality departments at ClearFlow Inc., the clinical department of the Heart Valve Therapy business at Edwards Lifesciences, the clinical department at Broncus Technologies, and was the director of clinical research at Medtronic Vascular. Dr. Gal holds a BSc. degree in biology from Tel Aviv University, Tel Aviv Israel, Doctor of Veterinary Medicine degree from Pisa University, Pisa Italy, and an MBA degree from Boston University, Boston, Massachusetts.